Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.16 -0.48% -0.02
AQST closed down 1.88 percent on Thursday, April 22, 2021, on 54 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AQST trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish -0.48%
Spinning Top Other -0.48%
Wide Bands Range Expansion -0.48%
Oversold Stochastic Weakness -0.48%
Outside Day Range Expansion -2.35%
Wide Bands Range Expansion -2.35%
Oversold Stochastic Weakness -2.35%
Wide Bands Range Expansion 6.12%
Down 3 Days in a Row Weakness 6.12%
Down 4 Days in a Row Weakness 6.12%
Older End-of-Day Signals for AQST ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance 12 minutes ago
Rose Above 10 DMA 30 minutes ago
Down 1% 30 minutes ago
Up 1% 30 minutes ago
60 Minute Opening Range Breakdown about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aquestive Therapeutics, Inc. Description

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Diseases Drugs Opioid Psychoactive Drugs Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Opioids Seizure Xone Seizures Gabaa Receptor Positive Allosteric Modulators Lactams Parkinson’s Disease Neuroendocrine Tumor Neuroendocrine Tumors Buprenorphine/Naloxone Riluzole

Is AQST a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Apr 21 AQST ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  Aquestive Therapeutics, Inc. – AQST
Apr 21 Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET
Apr 19 MGI, AQST & VLDR Class Action Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Apr 18 AQST INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AQST
Apr 16 LOSS ALERT: ROSEN, NATIONAL INVESTOR COUSNEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - AQST
Apr 16 ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action - AQST
Apr 16 MGI, AQST & VLDR Looming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Apr 14 MGI, AQST & VLDR Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Apr 12 Rosen, Leading Trial Attorneys, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AQST
Apr 12 FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
See more AQST news...

Indicators

Indicator Value
52 Week High 9.465
52 Week Low 3.67
Average Volume 904,873
200-Day Moving Average 5.88
50-Day Moving Average 4.93
20-Day Moving Average 4.51
10-Day Moving Average 4.28
Average True Range 0.35
ADX 16.38
+DI 17.94
-DI 24.20
Chandelier Exit (Long, 3 ATRs ) 4.37
Chandelier Exit (Short, 3 ATRs ) 4.92
Upper Bollinger Band 5.25
Lower Bollinger Band 3.78
Percent B (%b) 0.27
BandWidth 32.52
MACD Line -0.23
MACD Signal Line -0.20
MACD Histogram -0.031
Fundamentals Value
Market Cap 140.53 Million
Num Shares 33.6 Million
EPS -2.61
Price-to-Earnings (P/E) Ratio -1.60
Price-to-Sales 3.96
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.57
Resistance 3 (R3) 4.58 4.47 4.51
Resistance 2 (R2) 4.47 4.37 4.46 4.48
Resistance 1 (R1) 4.32 4.31 4.27 4.31 4.46
Pivot Point 4.21 4.21 4.18 4.20 4.21
Support 1 (S1) 4.06 4.11 4.01 4.05 3.90
Support 2 (S2) 3.95 4.05 3.94 3.88
Support 3 (S3) 3.80 3.95 3.86
Support 4 (S4) 3.79